Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$5.02 USD
+0.14 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United States in late July 2017 for the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche’s Herceptin-based adjuvant therapy. The drug was approved in the European Union in September 2018. Nerlynx in combination with Roche’s Xeloda was approved by the Food and Drug Administration (FDA) for third-line HER2-positive metastatic breast cancer in February 2020.
Nerlynx recorded sales worth $203.1 million ...
Company Summary
Los Angeles, CA-based Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United States in late July 2017 for the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche’s Herceptin-based adjuvant therapy. The drug was approved in the European Union in September 2018. Nerlynx in combination with Roche’s Xeloda was approved by the Food and Drug Administration (FDA) for third-line HER2-positive metastatic breast cancer in February 2020.
Nerlynx recorded sales worth $203.1 million in 2023, up 1.6% year over year.
Puma Biotech markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.
In September 2022, Puma Biotech in-licensed global development and commercialization rights to alisertib, an aurora kinase A inhibitor, from Japan’s Takeda. Puma Biotech plans to develop alisertib for the treatment of hormone receptor-positive breast cancer as well as small-cell lung cancer (SCLC).
Alisertib is now Puma Biotech's second project in clinical-stage development. If alisertib is successfully developed for the mentioned indications, it could enhance Puma Biotech's position in the market for anti-cancer drugs.
The company recorded total revenues of $235.6 million for 2023 compared with $228 million reported in 2022.
General Information
Puma Biotechnology, Inc
10880 WILSHIRE BOULEVARD SUITE 2150
LOS ANGELES, CA 90024
Phone: 424-248-6500
Fax: 424-248-6501
Web: http://www.pumabiotechnology.com
Email: ir@pumabiotechnology.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.16 |
Current Year EPS Consensus Estimate | 0.51 |
Estimated Long-Term EPS Growth Rate | 6.10 |
Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 4.88 |
52 Week High | 7.73 |
52 Week Low | 2.13 |
Beta | 1.28 |
20 Day Moving Average | 309,972.69 |
Target Price Consensus | 5.00 |
4 Week | -5.28 |
12 Week | 2.66 |
YTD | 15.94 |
4 Week | -2.42 |
12 Week | -1.24 |
YTD | 6.48 |
Shares Outstanding (millions) | 48.21 |
Market Capitalization (millions) | 242.00 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 9.91 |
Trailing 12 Months | 7.49 |
PEG Ratio | 1.62 |
vs. Previous Year | 316.67% |
vs. Previous Quarter | 116.67% |
vs. Previous Year | 9.89% |
vs. Previous Quarter | 28.70% |
Price/Book | 4.47 |
Price/Cash Flow | 7.21 |
Price / Sales | 1.03 |
3/31/24 | NA |
12/31/23 | 58.21 |
9/30/23 | 12.69 |
3/31/24 | NA |
12/31/23 | 10.40 |
9/30/23 | 1.80 |
3/31/24 | NA |
12/31/23 | 1.57 |
9/30/23 | 1.86 |
3/31/24 | NA |
12/31/23 | 1.50 |
9/30/23 | 1.78 |
3/31/24 | NA |
12/31/23 | 9.16 |
9/30/23 | 1.61 |
3/31/24 | NA |
12/31/23 | 9.16 |
9/30/23 | 1.61 |
3/31/24 | NA |
12/31/23 | 9.62 |
9/30/23 | 1.99 |
3/31/24 | NA |
12/31/23 | 1.12 |
9/30/23 | 0.81 |
3/31/24 | NA |
12/31/23 | 10.33 |
9/30/23 | 10.16 |
3/31/24 | NA |
12/31/23 | 1.23 |
9/30/23 | 1.98 |
3/31/24 | NA |
12/31/23 | 55.13 |
9/30/23 | 66.42 |